Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Payables (2020 - 2026)

Nautilus Biotechnology has reported Payables over the past 7 years, most recently at $1.2 million for Q1 2026.

  • Quarterly results put Payables at $1.2 million for Q1 2026, up 41.02% from a year ago — trailing twelve months through Mar 2026 was $1.2 million (up 41.02% YoY), and the annual figure for FY2025 was $943000.0, down 4.46%.
  • Payables reached $1.2 million in Q1 2026 per NAUT's latest filing, up from $943000.0 in the prior quarter.
  • Across five years, Payables topped out at $1.9 million in Q1 2024 and bottomed at $823000.0 in Q3 2022.
  • Median Payables over the past 5 years was $1.2 million (2023), compared with a mean of $1.2 million.
  • The largest annual shift saw Payables surged 1172.82% in 2022 before it tumbled 54.78% in 2025.
  • Over 5 years, Payables stood at $1.3 million in 2022, then increased by 28.85% to $1.6 million in 2023, then tumbled by 39.78% to $987000.0 in 2024, then dropped by 4.46% to $943000.0 in 2025, then grew by 25.77% to $1.2 million in 2026.
  • Business Quant data shows Payables for NAUT at $1.2 million in Q1 2026, $943000.0 in Q4 2025, and $893000.0 in Q3 2025.